You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 135 No. 7, July 2000 TABLE OF CONTENTS
  Archives
  •  Online Features
  Original Article
 This Article
 •Full text
 •PDF
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citing articles on ISI (5)
 •Contact me when this article is cited
 Related Content
 •Similar articles in this journal
 Topic Collections
 •Endocrine Surgery
 •Otolaryngology/ Head & Neck Surgery
 •Alert me on articles by topic

Preoperative Sestamibi Scanning and Surgical Findings at Bilateral, Unilateral, or Minimal Reoperation for Recurrent Hyperparathyroidism After Subtotal Parathyroidectomy in Patients With Multiple Endocrine Neoplasia Type 1

Joseph J. Shepherd, MD, FRACS; John R. Burgess, MD, FRACP; Timothy M. Greenaway, PhD, FRACP; Robert Ware, FCP

Arch Surg. 2000;135:844-848.

Hypotheses  Preoperative parathyroid radioisotope scanning is of little or no value in patients with multiple endocrine neoplasia type 1 when 4 or more hypertrophied glands are present. Scanning using technetium Tc 99m sestamibi and single photon emission computed tomography will achieve a high level of sensitivity and specificity after 3 or more glands have previously been removed, justifying limited surgical reexploration.

Design  In a prospective study, the preoperative documented report of the predicted site of residual parathryoid was compared with the surgical findings in 13 patients having 19 scans and 17 reoperations.

Setting  All patients belonged to one family, previously described as Tasman family 1, and were confirmed by genetic testing as having multiple endocrine neoplasia type 1. In 10 of 13 patients, reexploration was being undertaken more than 10 years after the first operation.

Main Outcome Measures  Scanning was regarded as successful when the documented preoperative report correctly predicted the side and quadrant in which a gland was found at surgery. Surgery was regarded as successful when calcium levels decreased to or below normal levels and were maintained.

Results  All 13 scans before first reexploration were successful in identifying the location of a residual parathyroid. From a statistical viewpoint, this equates to 100% sensitivity and 92% specificity. However, despite accurate localization of 1 residual gland in every patient, 7 supernumerary glands in 4 patients and 1 parathyroid remnant in a fifth patient were not localized so that sensitivity in locating all glands in every patient was only 61%. Scans performed for persistent hypercalcemia 48 to 72 hours after reexploration in 2 patients were unsuccessful in demonstrating any residual parathyroid. Scans performed 3 months after surgery in the same 2 patients and a third patient were successful, with sensitivity and specificity of 100%. Apart from patient 11, who awaits reexploration, normocalcemia was eventually achieved in every patient, with 11 of 12 having an initial period of hypocalcemia.

Conclusions  Three months after reexploration and trimming or resection with transplant of half a gland left at first operation, sestamibi scanning achieved sensitivity and specificity of 100% in locating supernumerary parathyroids in patients with multiple endocrine neoplasia type 1 and persistent hypercalcemia. Before first reexploration, however, scans rarely provided new information, predominantly showing only the hypertrophied half-gland remnant.


From the Departments of Surgery (Dr Shepherd), Endocrinology (Drs Burgess and Greenaway), and Nuclear Medicine (Dr Ware), University of Tasmania and Royal Hobart Hospital, Hobart, Tasmania, Australia.







HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2000 American Medical Association. All Rights Reserved.